Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Roche Fined For Anticompetitive Behavior In Romania

Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products. 

Romania Government Payers

EU Parallel Trade: The ‘Most Effective Savings Tool Available’

The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.

Europe Denmark

EMA Suspends Leo’s Actinic Keratosis Drug Picato

The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.

Europe Drug Safety

Australian Fees To Rise As Drug Registrations Decline

The Therapeutic Goods Administration says that its cost-recovery fees need to go up, mainly because of a fall in the number of medicines on the therapeutic products register. It is also seeing a rise in the cost of the fee-free services it provides.

Australia Regulation

Australian Fees To Rise As Registrations Decline

The Therapeutic Goods Administration says that its cost-recovery fees need to go up, mainly because of a fall in the number of products on the therapeutic products register. It is also seeing a rise in the cost of the fee-free services it provides.

Australia Regulation

EU Single Patent System On Course For 2020

Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.

Intellectual Property Regulation
See All
UsernamePublicRestriction

Register